D. Bafaloukos

发表

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

F. Siannis, I. Dahabreh, P. Kosmidis, 2008, The Lancet. Oncology.

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

K. Syrigos, T. Economopoulos, G. Fountzilas, 2012, BMC Cancer.

Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.

M. Dimopoulos, K. Syrigos, I. Boukovinas, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.

G. Aravantinos, G. Fountzilas, P. Kosmidis, 2015, Histology and histopathology.

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab

G. Fountzilas, G. Pentheroudakis, A. Batistatou, 2012, Journal of Translational Medicine.

Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation

George Fountzilas, Christos Christodoulou, T. Economopoulos, 2008, Cancer investigation.

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

G. Aravantinos, H. Kalofonos, G. Fountzilas, 2010, BMC medicine.

Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study

G. Lazaridis, A. Psyrri, K. Papadopoulou, 2018, PloS one.

PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients

G. Aravantinos, H. Kalofonos, G. Fountzilas, 2015, Cancer Chemotherapy and Pharmacology.

Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.

G. Fountzilas, G. Pentheroudakis, C. Papandreou, 2011, Anticancer research.

Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.

H. Gogas, G. Fountzilas, D. Pectasides, 2004, Anticancer research.

Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.

C. Papadimitriou, H. Linardou, D. Bafaloukos, 2012, Cancer treatment reviews.

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study

F. Fostira, D. Yannoukakos, H. Gogas, 2012, Breast Cancer Research and Treatment.

Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia.

G. Aravantinos, G. Fountzilas, G. Mountzios, 2016, Molecular and clinical oncology.

Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group

M. Dimopoulos, K. Syrigos, I. Boukovinas, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.

H. Gogas, K. Pavlakis, H. Kalofonos, 2010, Clinical breast cancer.

Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).

M. Dimopoulos, K. Syrigos, H. Kalofonos, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.

H. Gogas, G. Aravantinos, K. Papadopoulou, 2017, Cancer genomics & proteomics.

Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial

H. Gogas, C. Papadimitriou, C. Markopoulos, 2022, British Journal of Cancer.

Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.

M. Dimopoulos, K. Syrigos, I. Boukovinas, 2012, Anticancer research.

Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study.

M. Dimopoulos, N. Pavlidis, H. Gogas, 2005, Anticancer research.

Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group

I. Boukovinas, G. Aravantinos, A. Psyrri, 2020, ESMO Open.

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

D. Schadendorf, P. Ascierto, R. Dummer, 2019, European journal of cancer.

Baldness and other correlates of sex hormones in relation to testicular cancer

D. Trichopoulos, E. Petridou, N. Dessypris, 1997, International journal of cancer.

Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer.

H. Gogas, G. Lazaridis, G. Aravantinos, 2017, Anticancer research.

Protein expression patterns of cell cycle regulators in operable breast cancer

G. Lazaridis, C. Papadimitriou, G. Aravantinos, 2017, PloS one.

Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.

K. Papadopoulou, G. Fountzilas, G. Pentheroudakis, 2019, Clinical colorectal cancer.

Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.

G. Aravantinos, H. Kalofonos, G. Fountzilas, 2011, Oncology reports.

Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma.

J. Kirkwood, H. Gogas, A. Stratigos, 2020, The oncologist.

Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study

H. Kalofonos, G. Fountzilas, A. Bamias, 2005, Gastric Cancer.

Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations.

C. Papadimitriou, H. Linardou, D. Bafaloukos, 2011, Current medicinal chemistry.

Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group

K. Syrigos, V. Georgoulias, H. Gogas, 2021, Cancer Immunology, Immunotherapy.

Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy—A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study

A. Charchanti, H. Gogas, G. Aravantinos, 2022, Cancers.

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer

H. Gogas, G. Aravantinos, A. Psyrri, 2016, Journal of Translational Medicine.

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting

M. Dimopoulos, E. Giannoulatou, H. Gogas, 2016, Oncotarget.

Intravenous high‐dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta‐analysis of three trials

H. Gogas, A. Marshall, G. Fountzilas, 2015, Cancer medicine.

Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer

G. Fountzilas, D. Pectasides, A. Batistatou, 2021, AntiCancer Research.

Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond

K. Syrigos, G. Samonis, D. Bafaloukos, 2023, Cancers.

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

N. Pavlidis, S. Tejpar, G. Fountzilas, 2013, BMC Cancer.

The fate of BRCA1-related germline mutations in triple-negative breast tumors.

F. Fostira, D. Yannoukakos, H. Gogas, 2017, American journal of cancer research.

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

Issa J. Dahabreh, I. Dahabreh, P. Kosmidis, 2009, Nature Reviews Clinical Oncology.

The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial

George Fountzilas, Christos Christodoulou, George Kouvatseas, 2012, Breast Cancer Research.

Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.

M. Dimopoulos, G. Fountzilas, P. Kosmidis, 2008, Gynecologic Oncology.

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database

Issa J Dahabreh, I. Dahabreh, P. Kosmidis, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

G. Fountzilas, G. Pentheroudakis, C. Scopa, 2015, BMC Cancer.

All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer.

I. Dahabreh, P. Kosmidis, G. Mountzios, 2011, Cancer treatment reviews.

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel

M. Dimopoulos, U. Dafni, H. Gogas, 2012, PloS one.

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

M. Dimopoulos, U. Dafni, H. Gogas, 2012, Breast Cancer Research and Treatment.

Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial

C. Papadimitriou, G. Fountzilas, G. Pentheroudakis, 2013, PloS one.

H. Gogas, R. Wirtz, G. Fountzilas, 2012, Breast Cancer Research.

EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.

I. Dahabreh, H. Linardou, D. Bafaloukos, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial

M. Dimopoulos, H. Gogas, G. Lazaridis, 2018, PloS one.

Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

F. Siannis, I. Dahabreh, P. Kosmidis, 2009, Clinical Cancer Research.

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece

P. Papantoniou, G. Aravantinos, G. Fountzilas, 2021, Lung Cancer.

Lymphocyte Subpopulations and Interleukin Levels in High-Risk Melanoma Patients Treated With High-Dose Interferon A-2B

M. Mihm, H. Gogas, G. Paterakis, 2002, American journal of clinical oncology.

A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines.

G. Fountzilas, P. Kosmidis, D. Bafaloukos, 1996, European journal of cancer.

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study

H. Gogas, G. Aravantinos, K. Papadopoulou, 2015, PloS one.

Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG).

H. Gogas, G. Fountzilas, G. Pentheroudakis, 2015, Anticancer research.

Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.

U. Dafni, H. Gogas, G. Fountzilas, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study

H. Gogas, R. Wirtz, G. Aravantinos, 2015, Journal of Translational Medicine.

Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group

H. Gogas, C. Markopoulos, G. Fountzilas, 2005, Breast Cancer Research and Treatment.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial

N. Pavlidis, H. Gogas, R. Wirtz, 2009, Breast Cancer Research and Treatment.

Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial

H. Gogas, C. Papadimitriou, C. Markopoulos, 2022, British Journal of Cancer.

The role of taxanes in the treatment of metastatic melanoma

H. Gogas, A. Bedikian, D. Bafaloukos, 2004, Melanoma research.

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)

P. Ascierto, M. Del Vecchio, I. Krajsová, 2021, Cancers.

Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy

M. Dimopoulos, H. Gogas, R. Wirtz, 2018, Cancer medicine.

Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study

A. Bamias, H. Linardou, D. Bafaloukos, 2004, Journal of Neuro-Oncology.

Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG)

D. Bafaloukos, D. Skarlos, T. Makatsoris, 2005, Cancer Chemotherapy and Pharmacology.

Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group.

U. Dafni, T. Economopoulos, K. Syrigos, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).

D. Schadendorf, P. Ascierto, R. Dummer, 2019, European journal of cancer.

Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.

H. Gogas, T. Economopoulos, E. Kastritis, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.

H. Gogas, G. Chalkiadakis, C. Ioannou, 2010, Oncology reports.

Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors.

H. Gogas, H. Linardou, D. Bafaloukos, 2019, Melanoma research.

A Randomized Open-Label Parallel-Group Study Comparing Ondansetron with Ondansetron plus Dexamethasone in Patients with Metastatic Breast Cancer Receiving High-Dose Epirubicin. A Hellenic Cooperative Oncology Group Study

N. Pavlidis, G. Fountzilas, P. Kosmidis, 2000, Tumori.

Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects

G. Samonis, D. Bafaloukos, I. Gazouli, 2023, Vaccines.

Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.

M. Dimopoulos, G. Fountzilas, A. Bamias, 2008, Gynecologic oncology.

A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study

M. Dimopoulos, G. Aravantinos, T. Economopoulos, 2011, BMC medicine.

Targeting angiogenesis for the treatment of advanced melanoma

H. Linardou, D. Bafaloukos, 2011 .

Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative

E. Giannoulatou, H. Gogas, Jianhua Zhang, 2020, Oncotarget.

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab

S. Tejpar, A. Psyrri, G. Fountzilas, 2014, Journal of Cancer Research and Clinical Oncology.

Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma

F. Fostira, C. Papadimitriou, G. Aravantinos, 2021, Cancers.

Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)

M. Dimopoulos, G. Aravantinos, G. Fountzilas, 2004, Anti-cancer drugs.

Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.

H. Gogas, R. Wirtz, K. Pavlakis, 2015, Anticancer research.

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

M. Dimopoulos, U. Dafni, N. Pavlidis, 2014, BMC Cancer.

Docetaxel and Gemcitabine in Anthracycline-Resistant Advanced Breast Cancer: A Hellenic Cooperative Oncology Group Phase II Study

N. Pavlidis, G. Aravantinos, G. Fountzilas, 2000, Cancer investigation.

A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

N. Pavlidis, G. Fountzilas, G. Pentheroudakis, 2014, BMC Cancer.

The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab

I. Papassotiriou, O. Nicolatou‐Galitis, H. Linardou, 2019, Supportive Care in Cancer.

Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.

A. Bamias, C. Deliveliotis, E. Efstathiou, 2004, Urology.

K. Syrigos, T. Economopoulos, G. Fountzilas, 2012, BMC Cancer.

Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.

M. Dimopoulos, C. Papadimitriou, E. Efstathiou, 2002, Gynecologic oncology.

Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?

H. Gogas, C. Markopoulos, G. Fountzilas, 2020, Cancer Immunology, Immunotherapy.

Dose-Dense Adjuvant Chemotherapy with Epirubicin Monotherapy in Patients with Operable Breast Cancer and ≥10 Positive Axillary Lymph Nodes

N. Pavlidis, G. Aravantinos, G. Fountzilas, 1998, Oncology.

G. Fountzilas, G. Pentheroudakis, C. Scopa, 2015, BMC Cancer.

Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.

K. Syrigos, N. Pavlidis, G. Aravantinos, 2008, Critical reviews in oncology/hematology.

Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women

N. Pavlidis, H. Gogas, H. Kalofonos, 2006, Breast Cancer Research and Treatment.

The prevalence of autoantibodies in patients with high risk melanoma receiving adjuvant interferon

H. Gogas, I. Potouridou, A. Stratigos, 2004 .

Differential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes

H. Gogas, Anastasios Stofas, G. Fountzilas, 2014, PloS one.

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer

H. Gogas, G. Aravantinos, A. Psyrri, 2016, Journal of Translational Medicine.

Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab

K. Papadopoulou, G. Fountzilas, G. Pentheroudakis, 2018, Cancer Genomics & Proteomics.

Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.

M. Dimopoulos, C. Papadimitriou, G. Aravantinos, 2008, European Journal of Cancer.

Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens

K. Pavlakis, K. Papadopoulou, G. Fountzilas, 2021, Cancer research and treatment.

Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients

P. Papantoniou, G. Aravantinos, A. Psyrri, 2023, AntiCancer Research.

Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.

N. Pavlidis, H. Gogas, R. Wirtz, 2012, Clinical breast cancer.

A Phase II study of 2-weekly high-dose Epirubicin with r-met-hu G-CSF in advanced breast cancer

N. Pavlidis, G. Fountzilas, P. Kosmidis, 1994 .

Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients.

M. Dimopoulos, H. Gogas, G. Aravantinos, 2016, Clinical breast cancer.

AMALTHEA: Prospective, Single‐Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First‐Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer

G. Aravantinos, C. Petraki, G. Fountzilas, 2018, Clinical colorectal cancer.

Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival

M. Dimopoulos, N. Pavlidis, H. Gogas, 2006, Breast Cancer Research and Treatment.

Recombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma.

N. Pavlidis, G. Fountzilas, D. Bafaloukos, 1996, American journal of clinical oncology.

A New Mathematical Model for the Interpretation of Translational Research Evaluating Six CTLA-4 Polymorphisms in High-Risk Melanoma Patients Receiving Adjuvant Interferon

J. Kirkwood, H. Gogas, C. Markopoulos, 2014, PloS one.

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study

H. Gogas, R. Wirtz, G. Aravantinos, 2015, Journal of Translational Medicine.

High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group study.

N. Pavlidis, G. Fountzilas, P. Kosmidis, 1995, Medical and pediatric oncology.

Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer.

N. Pavlidis, G. Fountzilas, C. Bamia, 1994, European journal of cancer.

Irinotecan and Oxaliplatin Combination, As Second-Line Treatment, In Fluoropyrimidine-Pretreated Advanced Colorectal Cancer. A Phase Ii Study by the Hellenic Cooperative Oncology Group (Hecog)

G. Aravantinos, G. Fountzilas, D. Bafaloukos, 2005 .

Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

F. Siannis, I. Dahabreh, P. Kosmidis, 2009, Clinical Cancer Research.

G. Aravantinos, H. Kalofonos, G. Fountzilas, 2010, BMC medicine.

Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015–2018 in Greece. The ‘SUMMER’ study: a retrospective multicenter chart review project

D. Bafaloukos, K. Kalbakis, Panagiotis Kouzis, 2023, Melanoma research.